Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106915 | PMC |
| http://dx.doi.org/10.1016/j.jneuroim.2022.577850 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands.
Neuromuscul Disord
November 2024
Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Instituto Neurologico Carlo Besta, Milano, Italy. Electronic address:
The 275th ENMC workshop on the diagnosis and management of seronegative myasthenia gravis (SNMG) was held on February 9-11, 2024. The participants included experts in the field of adult and pediatric MG together with patient representatives. This workshop aimed to redefine SNMG in view of recent diagnostic and therapeutic updates and to identify patient unmet needs.
View Article and Find Full Text PDFDiagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows.
Brain Sci
September 2023
Neurology Unit, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, 90127 Palermo, Italy.
Myasthenia gravis (MG) is an antibody-mediated neuromuscular disease affecting the neuromuscular junction. In most cases, autoantibodies can be detected in the sera of MG patients, thus aiding in diagnosis and allowing for early screening. However, there is a small proportion of patients who have no detectable auto-antibodies, a condition termed "seronegative MG" (SnMG).
View Article and Find Full Text PDFAutoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis.
Neuromuscul Disord
February 2023
Department of Neurology and NeuroCure Clinical Research Center, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Autoantibody testing is the mainstay in confirming the diagnosis of autoimmune myasthenia gravis (MG). However, in approximately 15% of patients, antibody testing in clinical routine remains negative (seronegative MG). This study aimed at assessing the prevalence of "clustered" AChR- and MuSK- and LRP4- autoantibodies using a live cell-based assay in a large German cohort of seronegative myasthenia gravis (SNMG) patients.
View Article and Find Full Text PDFClinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
J Neurol Neurosurg Psychiatry
September 2022
Neuroscience Department, Catholic University of the Sacred Heart, Rome, Italy.
Article Synopsis
- Patients with seronegative myasthenia gravis (SNMG) often lack detectable antibodies, but live cell-based assays (l-CBAs) can reveal additional antibodies to AChR, MuSK, and LRP4.
- In a study of 82 SNMG patients, 19.5% had antibodies to clustered AChR and 8.5% had MuSK antibodies; a combined assay effectively detected these antibodies more efficiently.
- Patients with these antibodies generally had milder disease and better outcomes when treated soon after diagnosis compared to those with traditional RIA-detected antibodies.
The clinical need for clustered AChR cell-based assay testing of seronegative MG.
J Neuroimmunol
June 2022
Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address:
Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!